Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Sell
39
EQ Quote, Financials, Valuation and Earnings
Last price:
$0.39
Seasonality move
:
35.03%
Day range:
$0.39 - $0.44
52-week range:
$0.36 - $1.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.36x
P/B ratio:
0.79x
Volume:
112.4K
Avg. volume:
146.9K
1-year change:
-73.08%
Market cap:
$15M
Revenue:
$41.1M
EPS (TTM):
-$0.23
Analysts' Opinion
-
Consensus RatingEquillium has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.00, Equillium has an estimated upside of 138.1% from its current price of $0.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.42.
Fair Value
-
According to the consensus of 2 analysts, Equillium has 138.1% upside to fair value with a price target of $1.00 per share.
EQ vs. S&P 500
-
Over the past 5 trading days, Equillium has underperformed the S&P 500 by -6.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Equillium does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Equillium revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Equillium reported revenues of $4.4M.
Earnings Growth
-
Equillium has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Equillium reported earnings per share of -$0.16.
Enterprise value:
-7.6M
EV / Invested capital:
--
Price / LTM sales:
0.36x
EV / EBIT:
--
EV / Revenue:
-0.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-20.47%
Net Income Margin (TTM):
-19.63%
Return On Equity:
-37.23%
Return On Invested Capital:
-37.23%
Operating Margin:
-106.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $36.1M | $41.1M | $9.2M | $4.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$39M | -$14.5M | -$8.3M | -$3.2M | -$4.7M | |
| EBITDA | -$61.3M | -$12.1M | -$7.6M | -$2.3M | -$5.4M | |
| Diluted EPS | -$1.90 | -$0.39 | -$0.23 | -$0.07 | -$0.16 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $85.2M | $83.4M | $76.7M | $49.3M | $25M | |
| Total Assets | $85.4M | $85.4M | $78.4M | $50.5M | $25.6M | |
| Current Liabilities | $7.2M | $8.9M | $32M | $27.6M | $6.4M | |
| Total Liabilities | $15.6M | $18.9M | $46.5M | $28M | $6.5M | |
| Total Equity | $69.9M | $66.5M | $31.9M | $22.6M | $19.1M | |
| Total Debt | -- | -- | $9M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.7M | -$21.8M | -$19M | -$5.7M | -$3.3M | |
| Cash From Investing | $18.7M | -$4.8M | $13.8M | -$5.6M | $6M | |
| Cash From Financing | -$1.2M | -$9.2M | $164K | $79K | $73K | |
| Free Cash Flow | -$9M | -$21.8M | -$19.1M | -$5.7M | -$3.3M | |
EQ
Sector
Market Cap
$15M
$35.8M
Price % of 52-Week High
22.22%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-73.08%
-38.89%
Beta (5-Year)
2.058
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.44
200-day SMA
Sell
Level
$0.77
Bollinger Bands (100)
Sell
Level
0.53 - 0.81
Chaikin Money Flow
Buy
Level
475K
20-day SMA
Sell
Level
$0.46
Relative Strength Index (RSI14)
Sell
Level
37.01
ADX Line
Sell
Level
25.33
Williams %R
Neutral
Level
-74.3598
50-day SMA
Sell
Level
$0.61
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Sell
Level
-1.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.6729)
Sell
CA Score
(Annual)
Level (-0.7385)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.6195)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Stock Forecast FAQ
In the current month, EQ has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The EQ average analyst price target in the past 3 months is $1.00.
-
Where Will Equillium Stock Be In 1 Year?
According to analysts, the consensus estimate is that Equillium share price will rise to $1.00 per share over the next 12 months.
-
What Do Analysts Say About Equillium?
Analysts are divided on their view about Equillium share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Equillium is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Equillium's Price Target?
The price target for Equillium over the next 1-year time period is forecast to be $1.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is EQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Equillium is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of EQ?
You can purchase shares of Equillium via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Equillium shares.
-
What Is The Equillium Share Price Today?
Equillium was last trading at $0.39 per share. This represents the most recent stock quote for Equillium. Yesterday, Equillium closed at $0.42 per share.
-
How To Buy Equillium Stock Online?
In order to purchase Equillium stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
